Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 18/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.50 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14959570 | 0.84 | NAMPT (0.55) | NAMPTDPP8DPP9 | |
| SCHEMBL3438648 | 0.79 | NOTUM (0.61) | NAMPTDPP8DPP9 | |
| SCHEMBL11929924 | 0.78 | DPP8 (0.53) | NAMPTDPP8DPP9 | |
| SCHEMBL12162569 | 0.77 | MAPK1 (0.53) | NAMPTDPP8DPP9 | |
| SCHEMBL17034782 | 0.77 | NAMPT (0.48) | NAMPTGAA | |
| SCHEMBL8203594 | 0.77 | DPP8 (0.55) | NAMPTDPP8DPP9 | |
| SCHEMBL29992618 | 0.77 | DPP8 (0.55) | NAMPTDPP8DPP9 | |
| SCHEMBL25678398 | 0.76 | NAMPT (0.52) | NAMPTDPP8DPP9 | |
| SCHEMBL17572894 | 0.75 | DPP8 (0.53) | NAMPTDPP8DPP9 | |
| SCHEMBL22169249 | 0.75 | DPP8 (0.53) | NAMPTDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11638762-B2 | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors | SEAGEN INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-20190314519-A1 | TARGETED DELIVERY OF NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | SEATTLE GENETICS, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| US-20160362398-A1 | AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-8445527-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-20120231998-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362398-A1 | AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, CFH | NAMPT 1845/4885GAA 3877/4885DPP8 2454/4885 |
| US-20190314519-A1 | TARGETED DELIVERY OF NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | NAMPT, NME4, NNMT | NAMPT 1/4885GAA 529/4885DPP8 1738/4885 |
| US-20120231998-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | NAMPT 1593/4885GAA 283/4885DPP8 907/4885 |
| US-11638762-B2 | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors | NAMPT, NME4, NNMT | NAMPT 1/4885GAA 529/4885DPP8 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.